MYASTHENIA GRAVIS*
Authors: WALTER M. BOOTHBY
Journal: Annals of Internal Medicine (1935)

Article1 August 1935MYASTHENIA GRAVIS(SIXTH REPORT)WALTER M. BOOTHBY, M.D., F.A.C.P.WALTER M. BOOTHBY, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-9-2-143 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn previous articles on myasthenia gravis3-6 I described in detail the classical picture of the disease and the results of treatment with glycine and ephedrine. In this paper I shall present some of the other features of the disease,† and will include in the bibliography a few of the more important recent articles on the subject.As all are aware, the mortality of myasthenia gravis has been considered to be high. Goldstein, in Oppenheim's textbook, reported, without any details, 26 deaths in 38 cases; this is a mortality of approximately 70 per cent. However, Goldstein himself saw only a few...Bibliography1. ADAMS M: Metabolic studies following the administration of glycine, Proc. Jr. Biol. Chem., 1933, c, iii. Google Scholar2. ADAMSPOWER MMH: Chemical studies of patients with myasthenia gravis and progressive muscular dystrophy, Proc. Staff Meetings of Mayo Clinic, 1934, ix, 589-599. Google Scholar2a. ADAMSPOWERBOOTHBY MMHWM: The influence of glycine on the excretion of creatine and creatinine, Am. Jr. Physiol., 1935, cxi, 596-610. CrossrefGoogle Scholar3. BOOTHBY WM: Myasthenia gravis: a preliminary report on the effect of treatment with glycine, Proc. Staff Meetings of Mayo Clinic, 1932, vii, 557-562. Google Scholar4. BOOTHBY WM: Myasthenia gravis: the effect of treatment with glycine and ephedrine; third report, Arch. Int. Med., 1934, liii, 39-45. CrossrefGoogle Scholar5. BOOTHBY WM: Myasthenia gravis: the onset and course of the disease; fourth report, Jr. Am. Med. Assoc., 1934, cii, 259-261. CrossrefGoogle Scholar6. BOOTHBY WM: Myasthenia gravis: effect of treatment with glycine and ephedrine; fifth report, Proc. Staff Meetings of Mayo Clinic, 1934, ix, 593-597. Google Scholar7. BOOTHBY WM: The clinical effect of glycine in progressive muscular dystrophy, in simple fatigability, and on normal controls, Proc. Staff Meetings of Mayo Clinic, 1934, ix, 600-603. Google Scholar8. BOOTHBY WM: Myasthenia gravis: second report on the effect of treatment with glycine, Proc. Staff Meetings of Mayo Clinic, 1932, vii, 737-756. Google Scholar9. BRANDHARRISSANDBERGRINGER EMMMAI: Studies on the origin of creatine. Abst. in: Am. Jr. Physiol., 1929, xc, 296-297. Google Scholar10. BRIEGLEB K: Myasthenia gravis pseudoparalytica: nach Selbstbeobachtungen, Med. Klin., 1934, xxx, 305-306. Google Scholar11. DENNY-BROWN D: Physostigmine and belladonna by mouth in myasthenia gravis (Letter), Lancet, 1935, i, 767. CrossrefGoogle Scholar12. EDGEWORTH H: Report of progress on use of ephedrine in case of myasthenia gravis, Jr. Am. Med. Assoc., 1930, xciv, 1136. CrossrefGoogle Scholar13. EDGEWORTH H: Effect of ephedrine in treatment of myasthenia gravis: second report, Jr. Am. Med. Assoc., 1933, c, 1401. CrossrefGoogle Scholar14. GOLDSTEIN K, In: H. OPPENHEIM'S Lehrbuch der Nervenkrankheiten, 1913, S. Karger, Berlin, Ed. 7, ii, p. 1645. Google Scholar15. HUBBLE D: Myasthenia gravis (Letter), Lancet, 1935, i, 841. Google Scholar16. LAURENT LP: Myasthenia gravis (Letter), Lancet, 1935, i, 841. CrossrefGoogle Scholar17. MILHORATTECHNERTHOMAS ATFK: Significance of creatine in progressive muscular dystrophy, and treatment of this disease with glycine, Proc. Soc. Exper. Biol. and Med., 1932, xxix, 609-611. CrossrefGoogle Scholar18. PRITCHARD EA: Use of "prostigmin" in treatment of myasthenia gravis, Lancet, 1935, i, 432-435. CrossrefGoogle Scholar19. REMEN L: Zur Pathogenese und Therapie der Myasthenia gravis pseudoparalytica. Deutsch. Ztschr. f. Nervenh., 1932, cxxviii, 66-78. CrossrefGoogle Scholar20. SCHMITT EO: Use of glycine in treatment of myasthenia gravis, ANN. INT. MED., 1934, vii, 948-959. Google Scholar21. THOMASMILHORATTECHNER KATF: Untersuchungen über die Herkunft des Kreatins. Ein Beitrag zur Behandlung progressiver Muskelatrophien mit Glykokoll (Vorläufige Mitteilung), Ztschr. f. physiol. Chem., 1932, ccv, 93-98. CrossrefGoogle Scholar22. WALKER MB: The treatment of myasthenia gravis with physostigmine (Letter), Lancet, 1934, i, 1200-1201. CrossrefGoogle Scholar23. WILDER RM: General discussion, Proc. Staff Meetings of Mayo Clinic, 1934, ix, 606-608. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Rochester, Minnesota*Read at the Philadelphia meeting of the American College of Physicians, April 29, 1935.From the Section on Clinical Metabolism, The Mayo Clinic, Rochester, Minnesota.†Motion pictures were shown after reading of the paper to illustrate the characteristic fatigability and effect of treatment thereon. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByTHE RÔLE OF ARGININE AND GLYCINE IN CHICK NUTRITIONCHEMICAL STUDIES IN MYASTHENIA GRAVIS*MILDRED ADAMS, PH.D., MARSCHELLE H. POWER, PH.D., WALTER M. BOOTHBY, M.D., F.A.C.P. 1 August 1935Volume 9, Issue 2Page: 143-149KeywordsGlycineMortalityMyasthenia gravis Issue Published: 1 August 1935 PDF DownloadLoading ...